证券代码：300171 证券简称：东富龙 公告编号：2024-025 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 1.董事会、监事会及除之外的董事、监事、高级管理人员保证季度报告的真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 □是 否 一、主要财务数据 公司是否需追溯调整或重述以前年度会计数据 □是 否 1 | --- | --- | |---------------------------------------------|----------| | 是 □ 否 | | | | 本报告期 | | 支付的优先股股利（元） | 0.00 | | 支付的永续债利息（元） | 0.00 | | 用最新股本计算的全面摊薄每股收益（元 / 股） | 0.0850 | | --- | --- | --- | |------------------------------------------------------------------------------------------------------------- ...

八、非经常性损益项目及金额 □适用 不适用 将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常 性损益项目界定为经常性损益项目的情况说明 东富龙科技集团股份有限公司 2023 年年度报告全文 公司的主营业务为制药装备的研发、生产、销售和技术服务等。根据中国证监会颁布 的《上市公司行业分类指引》（2012 年修订），公司属于专用设备制造业（分类代码： C35）。根据国家统计局颁布的《国民经济行业分类》国家标准（GB/T4754-2017），公司 属于专用设备制造业（分类代码：C35）中的印刷、制药、日化及日用品生产专用设备制 造（分类代码：C354）项下的子行业制药专用设备制造（分类代码 C3544）。 （2）制药装备行业发展现状 东富龙科技集团股份有限公司 2023 年年度报告全文 3、制药装备行业发展趋势 （3）模块化和定制化：制药装备行业越来越倾向于模块化设计和定制化生产。模块 化设计可以提高设备的灵活性和可维护性，同时也方便根据客户需求定制生产。这种趋势 使得制药企业能够更好地满足市场需求，提高竞争力。 东富龙科技集团股份有限公司 2023 年年度报告全文 二、报告期内公 ...

证券代码：300171 证券简称：东富龙 东富龙科技集团股份有限公司投资者关系活动记录表 编号：2023-005 □特定对象调研 □分析师会议 投资者关系活动 □媒体采访 □业绩说明会 类别 □新闻发布会 □路演活动 □现场参观 ■其他 电话会议 参与单位名称 电话通讯方式与会名单请见附件 及人员姓名 时间 2023年10 月27日 8：30—9：30 地点 电话会议 副总经理兼董事会秘书：王艳 上市公司接待 财务总监：陆德华 人员姓名 投资总监：张盟 1、公司 2023年前三季度经营情况介绍 答：2023年前三季度公司实现营业收入43.25 亿元，较 上年同期增长 13.31%，归属于上市公司股东的净利润 5.83 亿元，较上年同期减少 3.48%， 归属于上市公司扣非后净 利润 5.39亿元，较上年同期减少4.84%。 ...

证券代码：300171 证券简称：东富龙 公告编号：2023-047 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季 度报告中财务信息的真实、准确、完整。 1 （一） 主要会计数据和财务指标 | --- | --- | --- | --- | --- | |---------------------------------------|-------------------|-------------------------|-------------------|---------------------------| | | 本报告期 | 本报告期比上 年同期增减 | 年初至报告期末 | 年初至报告 期末比上年 | | 营业收入（元） | 1,374,336,583.25 | -1.13% | 4,325,047,311.88 | 同期增减 13.31% | | 归属于上市公司股东的 | 157,332,998.22 | -22.04% | 583,404,859.76 | ...

证券代码：300171 证券简称：东富龙 | --- | --- | |----------------|-----------------------| | | □特定对象调研 | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | □现场参观 ■其他 电话会议 参与单位名称 及人员姓名 电话通讯方式与会名单请见附件 时间 2023 年 8 月 29 日 8：30—9：30 地点 电话会议 董事长兼总经理：郑效东 上市公司接待 财务总监：郜志坚 人员姓名 副总经理兼董事会秘书：王艳 投资总监：张盟 1、公司 2023 年半年度经营情况介绍。 答：2023 年半年度公司实现营业收入 29.51 亿元，较上年同期 增长 21.58%，归属于上市公司股东的净利润 4.26 亿元，较上年同期 增长 5.82%，归属于上市公司扣非后净利润 3.93 亿元，较上年同期 增 5.72%。国内收入 23.69 亿元，占比 80.3%；国际收入 5.81 亿元， 投资者关系活动主 占比 19.7%，国际占比与上年度相比有小幅度增长。 要内容介绍 2、请公司解读公司毛利率降低的原因 ...

Share Issuance and Capital Structure - The company issued 120,000,000 new shares to specific investors, increasing the total shares from 635,415,040 to 760,702,540, with the proportion of restricted shares rising from 31.66% to 42.36%[7] - The company's total share capital increased from 755,415,040 to 755,523,040 after the listing of 108,000 restricted shares from the 2021 incentive plan[8] - The company's total share capital further increased to 760,702,540 after the listing of 5,179,500 restricted shares from the second vesting period of the 2021 incentive plan[9] - The company received approval from the China Securities Regulatory Commission to issue 120,000,000 new shares to specific investors, which were listed on the Shenzhen Stock Exchange on January 13, 2023[26] - The company's total share capital increased from 635,415,040 shares to 755,415,040 shares after the issuance of 120,000,000 restricted shares to specific investors[93] - The company received approval from the China Securities Regulatory Commission (CSRC) for its private placement of A-shares on October 17, 2022[81][85] - The company issued 120,000,000 A-shares at a price of 20.57 yuan per share, raising a total of 2,468,400,000.00 yuan, with a net fundraising amount of 2,428,313,465.44 yuan[125] - The company issued 120,000,000 shares on December 20, 2022, at a price of 20.57, and they were listed on January 13, 2023[140] Restricted Stock Incentive Plan - The company completed the registration of 7.078 million restricted shares for the first vesting period of the 2021 restricted stock incentive plan, with 352 participants, and the shares became tradable on May 20, 2022[61] - The company held its sixth board meeting on April 26, 2023, approving the cancellation of some unvested restricted shares and the achievement of the second vesting period conditions for the 2021 restricted stock incentive plan[62] - The company implemented a restricted stock incentive plan in 2021, with adjustments made to the list of激励对象 and the number of shares granted[96][97][98] - The company's restricted shares increased by 419,351 due to the expiration of the term of office of certain directors and senior management[109] - The company's restricted shares increased by 93,750 due to the appointment of a new R&D director[109] - The company's restricted shares increased by 24,307,243 for specific investors such as the Advanced Manufacturing Industry Investment Fund II[100] - The company's restricted shares increased by 14,584,346 for specific investors such as Junhe Licheng Investment Management Center[100] - The company's restricted shares increased by 13,612,056 for specific investors such as Gaoyi Xiaofeng 2 Fund[100] Financial Performance and Metrics - The company's monetary funds decreased from 4,710,070,214.21 to 3,543,443,055.34 as of June 30, 2023[107] - The company's trading financial assets increased from 282,700,577.90 to 922,097,183.04 as of June 30, 2023[107] - The company's accounts receivable increased from 1,260,559,830.70 to 1,636,534,944.00 as of June 30, 2023[107] - The company's inventory decreased from 3,899,309,956.37 to 3,797,199,449.86 as of June 30, 2023[107] - The company's total current assets decreased from 11,264,291,322.75 to 10,823,334,932.34 as of June 30, 2023[107] - As of the reporting period, the company's total assets amounted to 13,219,848,446.31 yuan, with non-current assets totaling 2,396,513,513.97 yuan[121] - The company's long-term equity investments were valued at 140,255,968.34 yuan, and other equity instrument investments stood at 123,696,668.28 yuan[121] - The company's total liabilities were 5,314,550,261.43 yuan, with current liabilities accounting for 5,174,146,102.05 yuan[122] - The company's owner's equity totaled 7,905,298,184.88 yuan, with minority interests amounting to 218,956,579.73 yuan[122] - The company's fixed assets were valued at 768,392,408.08 yuan, and construction in progress was 552,008,214.27 yuan[121] - The company's contract liabilities amounted to 3,622,178,825.91 yuan, reflecting significant customer prepayments[121] - The company's monetary funds stood at 1,916,984,011.55 yuan, indicating strong liquidity[122] - The company's total equity attributable to the parent company was 7,686,341,605.15 yuan, with retained earnings of 2,887,600,796.49 yuan[122] - Total operating revenue for the first half of 2023 reached 2,950,710,728.63 yuan, a 21.6% increase compared to 2,426,943,177.90 yuan in the same period last year[148] - Operating costs for the first half of 2023 were 2,348,381,092.30 yuan, up 23.4% from 1,902,871,463.41 yuan in the first half of 2022[150] - Net profit for the first half of 2023 was 459,844,218.74 yuan, a 7.8% increase from 426,576,111.98 yuan in the same period last year[150] - R&D expenses for the first half of 2023 were 164,161,267.32 yuan, an 8.4% increase compared to 151,400,254.02 yuan in the first half of 2022[150] - Total liabilities as of the end of the first half of 2023 were 4,012,557,080.62 yuan, a decrease of 8.2% from 4,370,452,797.42 yuan at the end of the first half of 2022[148] - Total equity as of the end of the first half of 2023 was 6,862,284,529.82 yuan, a 1.5% increase from 6,759,579,250.37 yuan at the end of the first half of 2022[148] - Sales expenses for the first half of 2023 were 147,178,732.99 yuan, a 34.5% increase compared to 109,476,770.34 yuan in the first half of 2022[150] - Financial expenses for the first half of 2023 showed a net income of 48,211,350.46 yuan, compared to an expense of 11,718,166.99 yuan in the same period last year[150] - Credit impairment losses for the first half of 2023 were 77,293,706.63 yuan, an 88.1% increase from 41,109,684.85 yuan in the first half of 2022[150] - Total assets as of the end of the first half of 2023 were 10,874,841,610.44 yuan, a 2.3% decrease from 11,130,032,047.79 yuan at the end of the first half of 2022[148] - Net cash flow from operating activities was -2,135,895.49 yuan, compared to -11,739,484.85 yuan in the same period last year[166] - Net cash flow from investing activities was -756,130,260.48 yuan, a significant decrease from 344,659,574.67 yuan in the same period last year[166] - Net cash flow from financing activities was -116,145,225.49 yuan, compared to -179,853,956.20 yuan in the same period last year[166] - Total cash and cash equivalents at the end of the period were 3,533,937,375.54 yuan, down from 4,706,804,219.30 yuan at the beginning of the period[166] - Revenue for the first half of 2023 was 2,362,465,134.16 yuan, an increase from 1,962,747,814.92 yuan in the same period last year[173] - Net profit attributable to shareholders of the parent company was 426,071,861.54 yuan, up from 402,651,466.95 yuan in the same period last year[173] - R&D expenses for the first half of 2023 were 62,104,795.13 yuan, slightly higher than 60,286,779.43 yuan in the same period last year[173] - Sales expenses increased to 126,384,109.56 yuan from 90,332,891.19 yuan in the same period last year[173] - Financial income was -46,731,407.98 yuan, compared to an expense of 15,763,382.80 yuan in the same period last year[173] - Basic earnings per share were 0.5640 yuan, down from 0.6384 yuan in the same period last year[173] - Interest income increased significantly to 20,115,687.37 yuan, compared to 7,233,948.63 yuan in the previous period[174] - Net profit for the period was 291,184,795.76 yuan, up from 266,020,776.21 yuan in the same period last year[174] - Operating cash flow was negative at -312,643,967.86 yuan, compared to -62,477,473.45 yuan in the previous period[175] - Investment cash flow was negative at -1,635,299,282.83 yuan, compared to -159,552,958.67 yuan in the previous period[177] - Cash and cash equivalents decreased by 1,743,479,996.59 yuan, compared to a decrease of 341,667,824.12 yuan in the previous period[177] - Sales revenue from goods and services was 2,034,917,601.65 yuan, down from 2,219,618,604.08 yuan in the previous period[175] - Payments for goods and services were 1,385,002,901.53 yuan, down from 1,602,230,413.01 yuan in the previous period[175] - Payments to employees increased to 538,048,184.32 yuan, up from 424,220,469.43 yuan in the previous period[175] - Tax payments increased to 265,066,907.13 yuan, up from 171,371,777.20 yuan in the previous period[175] - Investment income was 42,419,337.82 yuan, up from 30,284,729.04 yuan in the previous period[174] - Accounts receivable increased to 1,288,785,673.83 from 941,730,815.11, a growth of 36.8%[188] - Total current assets decreased to 6,294,276,783.27 from 8,106,877,958.50, a decline of 22.4%[188] - Long-term equity investments increased significantly to 3,937,216,159.98 from 2,445,763,731.66, a growth of 61.0%[188] - Total non-current assets rose to 4,580,564,827.17 from 3,023,154,089.29, an increase of 51.5%[188] - Total assets slightly decreased to 10,874,841,610.44 from 11,130,032,047.79, a marginal decline of 2.3%[188] - Contract liabilities decreased to 3,186,153,808.90 from 3,595,912,414.82, a reduction of 11.4%[188] - Inventory decreased to 1,652,548,922.66 from 1,720,299,071.30, a decline of 3.9%[188] - Prepayments decreased to 660,524,395.19 from 944,974,952.31, a reduction of 30.1%[188] - Other receivables decreased to 106,002,046.23 from 209,214,653.86, a decline of 49.3%[188] - Fixed assets decreased slightly to 296,715,694.74 from 304,154,419.92, a marginal decline of 2.4%[188] Shareholder Structure and Ownership - The top 10 shareholders include Shanghai Biomedical Industry Equity Investment Fund Partnership, which subscribed to 24,307,243 shares, and Guotou Zhaoshang Investment Management Co., Ltd., which also subscribed to 24,307,243 shares[116] - The total number of ordinary shareholders at the end of the reporting period is 29,074, with a 5% shareholding ratio[127] - Zheng Xiaodong, a domestic natural person, holds 34.07% of the shares, amounting to 259,189,008 shares[127] - Zheng Keqing, another domestic natural person, holds 16.52% of the shares, amounting to 125,667,408 shares[127] - Hong Kong Central Clearing Limited, an overseas legal entity, holds 4.26% of the shares, amounting to 32,432,570 shares[127] - Shanghai Biomedical Industry Equity Investment Fund Partnership holds 3.20% of the shares, amounting to 24,307,243 shares[127] - The total number of shares held by the top 10 shareholders is 268,287,652, with no changes during the reporting period[133] Dividend Policy - The company does not plan to distribute cash dividends, issue bonus shares, or convert capital reserves into share capital[91] International Expansion and Exchange Rate Impact - The company is focusing on international expansion, with increasing export business, which may be significantly impacted by exchange rate fluctuations[33] Pharmaceutical Industry and Customer Focus - The company's main customer base is in the pharmaceutical industry, and it is enhancing quality management by integrating ICHQ9, GMP, and other pharmaceutical-related management requirements to improve customer satisfaction[36] - The pharmaceutical industry is undergoing rapid changes, leading to increased competition and a potential decline in the company's core business profitability[38] Risk Management and Governance - The company is implementing measures to improve investment decision-making, enhance governance, and mitigate risks associated with external development[39] - The company is focusing on precision management to improve efficiency, including optimizing organizational structures, processes, and IT systems to build competitive platforms in sales, R&D, manufacturing, HR, and finance[40] - The company is strengthening post-investment management of acquired businesses to maximize risk mitigation and ensure strategic alignment[41] Environmental and Social Responsibility - The company is actively using green energy, such as solar power, to reduce electricity consumption in its facilities[48] - The company has established environmental protection regulations, including energy-saving initiatives, waste management, and emergency response plans for hazardous materials[64] - The company is committed to supporting education through scholarships and providing accessible, high-quality educational opportunities for local youth[59] Product and Industry Focus - The company's products are designed for the pharmaceutical, food, and medical industries, featuring customized stainless steel equipment with environmentally friendly components and advanced SCADA systems for automation[86] Financial Reporting and Disclosure - The company's financial report for the first half of 2023 is available on the official website[132] - The company's financial data and indicators are detailed in the "Company Profile and Major Financial Indicators" section of the report[138] - The company does not have any preferred shares during the reporting period[137]

治理层负责监督东富龙科技的财务报告过程。 我们的目标是对财务报表整体是否不存在由于舞弊或错误导致的重大错报获取合理保 证，并出具包含审计意见的审计报告。合理保证是高水平的保证，但并不能保证按照审计 准则执行的审计在某一重大错报存在时总能发现。错报可能由于舞弊或错误导致，如果合 理预期错报单独或汇总起来可能影响财务报表使用者依据财务报表作出的经济决策，则通 常认为错报是重大的。 （1）识别和评估由于舞弊或错误导致的财务报表重大错报风险，设计和实施审计程 序以应对这些风险，并获取充分、适当的审计证据，作为发表审计意见的基础。由于舞弊 可能涉及串通、伪造、故意遗漏、虚假陈述或凌驾于内部控制之上，未能发现由于舞弊导 致的重大错报的风险高于未能发现由于错误导致的重大错报的风险。 （3）评价管理层选用会计政策的恰当性和作出会计估计及相关披露的合理性。 东富龙科技集团股份有限公司 TOFFLON SCIENCE AND TECHNOLOGY GROUP CO.,LTD 上海市 闵行区 都会路 1509 号 东富龙科技集团股份有限公司 2022 年年度报告全文 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 ...

东富龙科技集团股份有限公司 2023 年第一季度报告 2023 年第一季度报告 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 □ 是 否 公司是否需追溯调整或重述以前年度会计数据 1 （二） 非经常性损益项目和金额 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 公司不存在将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》 中列举的非经常性损益项目界定为经常性损益的项目的情形。 1、资产负债表项目重大变动情况及原因说明 致； （5）资产减值损失较去年同期变动 56.47%，主要系本期合同资产减值较去年同期增 （1）经营活动产生的现金流量净额较去年同期变动 94.43%，主要系本期购买商品支 付的现金减少所致致； 单位：股 （二） 公司优先股股东总数及前 10 名优先股股东持股情况表 东富龙科技集团股份有限公司 2023 年第一季度报告 公司于 2022 年 10 月 17 日收到中国证监会出具的《关于同意东富龙科技集团股份有限 公司向特定对象发行股票注册的批复》（证监许可﹝2022﹞ ...

证券代码：300171 证券简称：东富龙 编号：2015-001 上海东富龙科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|--------------|--------------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 瑞银证券 吕学龙、李乐；施罗德基金 刘勍；华安基金 袁银 | | 人员姓名 | | 泉；平安租赁 胡锐；人保资产 黄海培；域秀资本 邵喆阳； | | | | 中欧基金 江琦、高喜阳；海通恒信国际租赁 冉凡春；鼎晖投 | | | | 资 李萌、王晓静；中信证券 胡正洋、刘芷冰；法国巴黎资本 | | | | 曹志荣；中山证券 陈岚静；上海美益金融投资 胡钰昕；宝弘 | | | | 资产 涂怀蓉、侍金璐 ...